[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @stellanewslife STELLANEWS.LIFE STELLANEWS.LIFE posts on X about $4523t, $4528t, acquisition, novartis the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1292752935533686785/interactions)  - X Week XXX -XX% - X Month XXXXX -XX% - X Months XXXXXX +202% - X Year XXXXXX +924% ### Mentions: XX [#](/creator/twitter::1292752935533686785/posts_active)  - X Week XX -XX% - X Month XXX -XX% - X Months XXX +113% - X Year XXX +846% ### Followers: XXX [#](/creator/twitter::1292752935533686785/followers)  - X Week XXX +1.50% - X Month XXX +2.70% - X Months XXX +23% - X Year XXX +36% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1292752935533686785/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) XXXXX% [finance](/list/finance) XXXXX% [currencies](/list/currencies) XXX% **Social topic influence** [$4523t](/topic/$4523t) #10, [$4528t](/topic/$4528t) #1, [acquisition](/topic/acquisition) #891, [novartis](/topic/novartis) #17, [combo](/topic/combo) 5.41%, [$4506t](/topic/$4506t) 2.7%, [$8053t](/topic/$8053t) 2.7%, [target](/topic/target) 2.7%, [longterm](/topic/longterm) 2.7%, [dividend](/topic/dividend) XXX% **Top assets mentioned** [Novartis AG (NVS)](/topic/novartis) [Eli Lilly and Company (LLY)](/topic/eli-lilly) ### Top Social Posts Top posts by engagements in the last XX hours "Sumitomo Pharma Presents New Clinical Data for Enzomenib and Nuvisertib at ASH 2025 🧬 At the American Society of Hematology (ASH) 2025 Annual Meeting Sumitomo Pharma shared new results for two investigational targeted therapies: enzomenib (menin inhibitor) and nuvisertib (PIM1 kinase inhibitor). 🔹 Key Findings Enzomenib monotherapy: ORR XXXX% CR/CRh XX% in AML with KMT2A rearrangement. Enzomenib + azacitidine/venetoclax: ORR XX% in treatment-nave AML. Nuvisertib: Demonstrated tolerability and symptom improvement in myelofibrosis. These data support continued development of both agents as" [X Link](https://x.com/stellanewslife/status/2000217525112742004) 2025-12-14T14:53Z XXX followers, XXX engagements "Eisais Anti-Tau Antibody Etalanetug Significantly Lowers Novel Biomarker eMTBR-tau243 At CTAD 2025 Eisai reported Phase Ib/II results showing that etalanetug (E2814) markedly reduced eMTBR-tau243 a new biomarker linked to tau pathology in both CSF and blood of participants with dominantly inherited Alzheimers disease. 🔬 Key data: CSF eMTBR-tau243 XX at X months XX at X months Blood eMTBR-tau243 XX at X months XX at X months Supports the mechanism of inhibiting tau seeding and spread Etalanetug is being tested with lecanemab (Leqembi) in the Tau NexGen Phase II/III trial and has received FDA" [X Link](https://x.com/stellanewslife/status/1997833781261238405) 2025-12-08T01:01Z XXX followers, XX engagements "Lecanemab Demonstrates Pharmacologic Effects on A Protofibrils in CSF CTAD 2025 At CTAD 2025 Eisai and Biogen presented new analyses from the Clarity AD Phase X trial showing that lecanemab (Leqembi) engages its target A protofibrils in cerebrospinal fluid. 🧠 Key findings (CSF subcohort n=410): Total A protofibrils XX at XX months (vs +19 in placebo p=0.0126) Positive correlations with tau/neuronal biomarkers seen in placebo absent in lecanemab group Suggests reduced neurotoxic impact of protofibrils via target engagement These data support lecanemabs dual mechanismbinding both toxic" [X Link](https://x.com/stellanewslife/status/1997834500345364990) 2025-12-08T01:03Z XXX followers, XX engagements "Lecanemab May Delay Alzheimers Progression by Up to XXX Years CTAD 2025 At CTAD 2025 Eisai and Biogen presented new long-term analyses showing that continuous lecanemab (Leqembi) treatment could delay progression from MCI to moderate Alzheimers disease by up to XXX years particularly in amyloid-low patients. 💡 Key Findings: MCI mild AD: delay XXX years (up to XXX years in amyloid-low group) MCI moderate AD: delay XXX years (up to XXX years in amyloid-low group) Subcutaneous lecanemab (SC-AI) showed pharmacokinetic equivalence to IV dosing (104%) Lower infusion reactions improved convenience" [X Link](https://x.com/stellanewslife/status/1997835164857307447) 2025-12-08T01:06Z XXX followers, XX engagements "Ono Pharmaceutical Named to CDP 2025 A List for Climate Change and Water Security 🌎💧 Ono Pharmaceutical Co. Ltd. announced that it has been recognized on the CDP 2025 A List for both Climate Change and Water Security. 🔹 Highlights X consecutive years on the Climate Change A List X consecutive years on the Water Security A List Recognized for ambitious targets and transparent disclosure under its ECO VISION 2050 Ongoing initiatives include GHG reduction water conservation and biodiversity protection Ono continues to integrate sustainability into its corporate mission delivering innovative" [X Link](https://x.com/stellanewslife/status/2000059380721738007) 2025-12-14T04:24Z XXX followers, XX engagements "Ono Pharma Reports Positive Phase IIa Results for Sapablursen in Polycythemia Vera 🧬 At the ASH 2025 Annual Meeting Ono Pharmaceutical presented positive topline results from the IMPRSSION Phase IIa trial evaluating sapablursen an investigational antisense oligonucleotide therapy for polycythemia vera (PV). 🔹 Key Findings Significant reduction in phlebotomy frequency Improved hematocrit control and increased hepcidin levels Well-tolerated with no major safety concerns Supports progression to a Phase III program This study highlights a potential new RNA-based approach to reduce transfusion" [X Link](https://x.com/stellanewslife/status/2000225918741274917) 2025-12-14T15:26Z XXX followers, XX engagements "Abbott Raises Quarterly Dividend for the 54th Consecutive Year 💵🏥 Abbott announced a XXX% increase in its quarterly dividend to $XXXX per share marking its 54th consecutive year of dividend growth. 🔹 Key Highlights Member of the S&P XXX Dividend Aristocrats Index Over XX% increase in total quarterly dividend payouts since 2020 Represents XXX consecutive dividend payments since 1924 Abbott continues to demonstrate long-term financial stability and a strong commitment to shareholder value while advancing healthcare innovation. 🔗 Read more: #Abbott #DividendAristocrat #ShareholderReturns" [X Link](https://x.com/stellanewslife/status/2000226840754163811) 2025-12-14T15:30Z XXX followers, XX engagements "Lecanemab (Leqembi) Added to Chinas Innovative Drug List for Commercial Health Insurance 🧬 Eisai and Biogen announced that lecanemab their Alzheimers disease treatment has been included in Chinas Commercial Insurance Innovative Drug List. 🔹 Key Points Policy to take effect January 2026 Designed to bridge the gap between public reimbursement and innovative therapies Aims to expand real-world access to disease-modifying treatments The inclusion marks a major step in improving access to advanced Alzheimers treatments for patients in China. 🔗 Read more: #Eisai #Biogen #Leqembi #Lecanemab" [X Link](https://x.com/stellanewslife/status/2000229812074696954) 2025-12-14T15:42Z XXX followers, XX engagements "Astellas to Present New Gastrointestinal Cancer Data at ASCO GI 2026 🔬 Astellas announced upcoming presentations at the ASCO Gastrointestinal Cancers Symposium 2026 highlighting advances in precision oncology. 🔹 Key Highlights Phase X ILUSTRO trial results for zolbetuximab combination therapy in CLDN18.2+ / HER2 gastric cancer (oral presentation) First-in-human Phase X data of ASP3082 a KRAS G12D degrader in pancreatic ductal adenocarcinoma Broader updates on Astellas precision medicine pipeline in GI oncology These studies reinforce Astellas commitment to developing novel targeted" [X Link](https://x.com/stellanewslife/status/2000230789750165616) 2025-12-14T15:45Z XXX followers, XX engagements "Novo Nordisk Completes Acquisition of Akero Therapeutics #NovoNordisk #AkeroTherapeutics #EFX #NASH #Biopharma #MergersAndAcquisitions #CVR" [X Link](https://x.com/stellanewslife/status/2000234112708403208) 2025-12-14T15:59Z XXX followers, XX engagements "Novo Nordisk Completes Acquisition of Akero Therapeutics #NovoNordisk #AkeroTherapeutics #EFX #NASH #Biopharma #MergersAndAcquisitions #CVR" [X Link](https://x.com/stellanewslife/status/2000234580520124554) 2025-12-14T16:01Z XXX followers, XX engagements "Lillys Retatrutide Succeeds in Phase X for Obesity and Knee Osteoarthritis #Retatrutide #EliLilly #Obesity #Osteoarthritis #GIP #GLP1 #Glucagon #IncretinTherapy #TRIUMPH4 #Phase3Trial" [X Link](https://x.com/stellanewslife/status/2000239021570887731) 2025-12-14T16:18Z XXX followers, XX engagements "Novartis Reports X in X Patients Remain Progression-Free Beyond X Years with Kisqali Combo in Metastatic Breast Cancer #Kisqali #Ribociclib #Novartis #MONALEESA #CDK46inhibitor #BreastCancer #HRpositive #HER2negative #EndocrineTherapy #PFS" [X Link](https://x.com/stellanewslife/status/2000244884071133288) 2025-12-14T16:41Z XXX followers, XX engagements "Novartis Reports Ianalumab Combo Extends Disease Control in Immune Thrombocytopenia (ITP) #Novartis #Ianalumab #ITP #PlateletDisorders #AutoimmuneDisease #VAYHIT2 #Biologics #Hematology #ClinicalTrials" [X Link](https://x.com/stellanewslife/status/2000245305678442756) 2025-12-14T16:43Z XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@stellanewslife STELLANEWS.LIFE
STELLANEWS.LIFE posts on X about $4523t, $4528t, acquisition, novartis the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXX -XX%
- X Month XXXXX -XX%
- X Months XXXXXX +202%
- X Year XXXXXX +924%
Mentions: XX #
- X Week XX -XX%
- X Month XXX -XX%
- X Months XXX +113%
- X Year XXX +846%
Followers: XXX #
- X Week XXX +1.50%
- X Month XXX +2.70%
- X Months XXX +23%
- X Year XXX +36%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence stocks XXXXX% finance XXXXX% currencies XXX%
Social topic influence $4523t #10, $4528t #1, acquisition #891, novartis #17, combo 5.41%, $4506t 2.7%, $8053t 2.7%, target 2.7%, longterm 2.7%, dividend XXX%
Top assets mentioned Novartis AG (NVS) Eli Lilly and Company (LLY)
Top Social Posts
Top posts by engagements in the last XX hours
"Sumitomo Pharma Presents New Clinical Data for Enzomenib and Nuvisertib at ASH 2025 🧬 At the American Society of Hematology (ASH) 2025 Annual Meeting Sumitomo Pharma shared new results for two investigational targeted therapies: enzomenib (menin inhibitor) and nuvisertib (PIM1 kinase inhibitor). 🔹 Key Findings Enzomenib monotherapy: ORR XXXX% CR/CRh XX% in AML with KMT2A rearrangement. Enzomenib + azacitidine/venetoclax: ORR XX% in treatment-nave AML. Nuvisertib: Demonstrated tolerability and symptom improvement in myelofibrosis. These data support continued development of both agents as"
X Link 2025-12-14T14:53Z XXX followers, XXX engagements
"Eisais Anti-Tau Antibody Etalanetug Significantly Lowers Novel Biomarker eMTBR-tau243 At CTAD 2025 Eisai reported Phase Ib/II results showing that etalanetug (E2814) markedly reduced eMTBR-tau243 a new biomarker linked to tau pathology in both CSF and blood of participants with dominantly inherited Alzheimers disease. 🔬 Key data: CSF eMTBR-tau243 XX at X months XX at X months Blood eMTBR-tau243 XX at X months XX at X months Supports the mechanism of inhibiting tau seeding and spread Etalanetug is being tested with lecanemab (Leqembi) in the Tau NexGen Phase II/III trial and has received FDA"
X Link 2025-12-08T01:01Z XXX followers, XX engagements
"Lecanemab Demonstrates Pharmacologic Effects on A Protofibrils in CSF CTAD 2025 At CTAD 2025 Eisai and Biogen presented new analyses from the Clarity AD Phase X trial showing that lecanemab (Leqembi) engages its target A protofibrils in cerebrospinal fluid. 🧠 Key findings (CSF subcohort n=410): Total A protofibrils XX at XX months (vs +19 in placebo p=0.0126) Positive correlations with tau/neuronal biomarkers seen in placebo absent in lecanemab group Suggests reduced neurotoxic impact of protofibrils via target engagement These data support lecanemabs dual mechanismbinding both toxic"
X Link 2025-12-08T01:03Z XXX followers, XX engagements
"Lecanemab May Delay Alzheimers Progression by Up to XXX Years CTAD 2025 At CTAD 2025 Eisai and Biogen presented new long-term analyses showing that continuous lecanemab (Leqembi) treatment could delay progression from MCI to moderate Alzheimers disease by up to XXX years particularly in amyloid-low patients. 💡 Key Findings: MCI mild AD: delay XXX years (up to XXX years in amyloid-low group) MCI moderate AD: delay XXX years (up to XXX years in amyloid-low group) Subcutaneous lecanemab (SC-AI) showed pharmacokinetic equivalence to IV dosing (104%) Lower infusion reactions improved convenience"
X Link 2025-12-08T01:06Z XXX followers, XX engagements
"Ono Pharmaceutical Named to CDP 2025 A List for Climate Change and Water Security 🌎💧 Ono Pharmaceutical Co. Ltd. announced that it has been recognized on the CDP 2025 A List for both Climate Change and Water Security. 🔹 Highlights X consecutive years on the Climate Change A List X consecutive years on the Water Security A List Recognized for ambitious targets and transparent disclosure under its ECO VISION 2050 Ongoing initiatives include GHG reduction water conservation and biodiversity protection Ono continues to integrate sustainability into its corporate mission delivering innovative"
X Link 2025-12-14T04:24Z XXX followers, XX engagements
"Ono Pharma Reports Positive Phase IIa Results for Sapablursen in Polycythemia Vera 🧬 At the ASH 2025 Annual Meeting Ono Pharmaceutical presented positive topline results from the IMPRSSION Phase IIa trial evaluating sapablursen an investigational antisense oligonucleotide therapy for polycythemia vera (PV). 🔹 Key Findings Significant reduction in phlebotomy frequency Improved hematocrit control and increased hepcidin levels Well-tolerated with no major safety concerns Supports progression to a Phase III program This study highlights a potential new RNA-based approach to reduce transfusion"
X Link 2025-12-14T15:26Z XXX followers, XX engagements
"Abbott Raises Quarterly Dividend for the 54th Consecutive Year 💵🏥 Abbott announced a XXX% increase in its quarterly dividend to $XXXX per share marking its 54th consecutive year of dividend growth. 🔹 Key Highlights Member of the S&P XXX Dividend Aristocrats Index Over XX% increase in total quarterly dividend payouts since 2020 Represents XXX consecutive dividend payments since 1924 Abbott continues to demonstrate long-term financial stability and a strong commitment to shareholder value while advancing healthcare innovation. 🔗 Read more: #Abbott #DividendAristocrat #ShareholderReturns"
X Link 2025-12-14T15:30Z XXX followers, XX engagements
"Lecanemab (Leqembi) Added to Chinas Innovative Drug List for Commercial Health Insurance 🧬 Eisai and Biogen announced that lecanemab their Alzheimers disease treatment has been included in Chinas Commercial Insurance Innovative Drug List. 🔹 Key Points Policy to take effect January 2026 Designed to bridge the gap between public reimbursement and innovative therapies Aims to expand real-world access to disease-modifying treatments The inclusion marks a major step in improving access to advanced Alzheimers treatments for patients in China. 🔗 Read more: #Eisai #Biogen #Leqembi #Lecanemab"
X Link 2025-12-14T15:42Z XXX followers, XX engagements
"Astellas to Present New Gastrointestinal Cancer Data at ASCO GI 2026 🔬 Astellas announced upcoming presentations at the ASCO Gastrointestinal Cancers Symposium 2026 highlighting advances in precision oncology. 🔹 Key Highlights Phase X ILUSTRO trial results for zolbetuximab combination therapy in CLDN18.2+ / HER2 gastric cancer (oral presentation) First-in-human Phase X data of ASP3082 a KRAS G12D degrader in pancreatic ductal adenocarcinoma Broader updates on Astellas precision medicine pipeline in GI oncology These studies reinforce Astellas commitment to developing novel targeted"
X Link 2025-12-14T15:45Z XXX followers, XX engagements
"Novo Nordisk Completes Acquisition of Akero Therapeutics #NovoNordisk #AkeroTherapeutics #EFX #NASH #Biopharma #MergersAndAcquisitions #CVR"
X Link 2025-12-14T15:59Z XXX followers, XX engagements
"Novo Nordisk Completes Acquisition of Akero Therapeutics #NovoNordisk #AkeroTherapeutics #EFX #NASH #Biopharma #MergersAndAcquisitions #CVR"
X Link 2025-12-14T16:01Z XXX followers, XX engagements
"Lillys Retatrutide Succeeds in Phase X for Obesity and Knee Osteoarthritis #Retatrutide #EliLilly #Obesity #Osteoarthritis #GIP #GLP1 #Glucagon #IncretinTherapy #TRIUMPH4 #Phase3Trial"
X Link 2025-12-14T16:18Z XXX followers, XX engagements
"Novartis Reports X in X Patients Remain Progression-Free Beyond X Years with Kisqali Combo in Metastatic Breast Cancer #Kisqali #Ribociclib #Novartis #MONALEESA #CDK46inhibitor #BreastCancer #HRpositive #HER2negative #EndocrineTherapy #PFS"
X Link 2025-12-14T16:41Z XXX followers, XX engagements
"Novartis Reports Ianalumab Combo Extends Disease Control in Immune Thrombocytopenia (ITP) #Novartis #Ianalumab #ITP #PlateletDisorders #AutoimmuneDisease #VAYHIT2 #Biologics #Hematology #ClinicalTrials"
X Link 2025-12-14T16:43Z XXX followers, XX engagements